Today, Adaptimmune Therapeutics PLC (ADAP) Receives $15.50 Consensus Target Price from Brokerages

Today, Adaptimmune Therapeutics PLC (ADAP) Receives $15.50 Consensus Target Price from Brokerages
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has been assigned a consensus rating of “Buy” from the eight research firms that are covering the company. Two analysts have rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $15.50.

ADAP has been the subject of a number of research reports. Zacks Investment Research lowered shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Raymond James Financial Inc. initiated coverage on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 30th. They set an “outperform” rating and a $16.00 target price for the company. Bank of America Corp. lowered shares of Adaptimmune Therapeutics PLC from a “neutral” rating to an “underperform” rating in a research report on Monday, October 24th. Cowen and Company reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Thursday, November 10th. Finally, Leerink Swann reiterated a “buy” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Friday, November 11th.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 4.98 on Wednesday. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $12.85. The company’s 50 day moving average is $5.04 and its 200 day moving average is $7.44.

A number of institutional investors have recently modified their holdings of ADAP. Adage Capital Partners GP L.L.C. increased its stake in shares of Adaptimmune Therapeutics PLC by 35.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $9,350,000 after buying an additional 300,000 shares during the last quarter. Springbok Capital Management LLC purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $202,000. Opaleye Management Inc. purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $1,425,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock worth $888,000 after buying an additional 3,519 shares during the last quarter. Finally, Rathbone Brothers plc increased its stake in shares of Adaptimmune Therapeutics PLC by 124.7% in the second quarter. Rathbone Brothers plc now owns 450,525 shares of the company’s stock worth $3,672,000 after buying an additional 250,000 shares during the last quarter. Hedge funds and other institutional investors own 45.05% of the company’s stock.

Related posts

Leave a Comment